Edogestrone

Edogestrone
Clinical data
Other namesEdogesterone; PH-218; 17α-Acetoxy-3,3-ethylenedioxy-6-methylpregn-5-en-20-one
Drug classProgestogen; Progestogen ester
Identifiers
  • [(8'R,9'S,10'R,13'S,14'S,17'R)-17'-acetyl-6',10',13'-trimethylspiro[1,3-dioxolane-2,3'-2,4,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene]-17'-yl] acetate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC26H38O5
Molar mass430.585 g·mol−1
3D model (JSmol)
  • CC1=C2CC3(CCC2(C4CCC5(C(C4C1)CCC5(C(=O)C)OC(=O)C)C)C)OCCO3
  • InChI=1S/C26H38O5/c1-16-14-19-20(23(4)10-11-25(15-22(16)23)29-12-13-30-25)6-8-24(5)21(19)7-9-26(24,17(2)27)31-18(3)28/h19-21H,6-15H2,1-5H3/t19-,20+,21+,23-,24+,26+/m1/s1
  • Key:UOYMGHSCINLOBK-ZKKYLISVSA-N

Edogestrone (INNTooltip International Nonproprietary Name, BANTooltip British Approved Name; development code PH-218; also known as edogesterone or 17α-acetoxy-3,3-ethylenedioxy-6-methylpregn-5-en-20-one) is a steroidal progestin and antiandrogen of the 17α-hydroxyprogesterone group which was synthesized in 1964 but was never marketed. Similarly to the structurally related steroid cyproterone acetate, edogestrone binds directly to the androgen receptor and antagonizes it, displacing androgens like testosterone from the receptor, though not as potently as cyproterone acetate. The drug has also been found to suppress androgen production, likely via progesterone receptor activation-mediated antigonadotropic activity.

See also